查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症基因治疗市场规模、份额和趋势分析报告：按疗法（溶瘤生物疗法、基因引导免疫疗法、基因转移）、最终用途、地区、细分市场预测 2022-2030 年
市场调查报告书
商品编码
1147481

癌症基因治疗市场规模、份额和趋势分析报告：按疗法（溶瘤生物疗法、基因引导免疫疗法、基因转移）、最终用途、地区、细分市场预测 2022-2030 年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

癌症基因治疗市场的增长和趋势

Grand View Research, Inc. 的一份新报告预测，到 2030 年，全球癌症基因治疗市场将达到 87 亿美元。由于全球对新疗法的需求不断增加以及全球癌症发病率不断上升，该市场预计从 2022 年到 2030 年的复合年增长率为 19.99%。此外，这种疗法为各种类型的遗传性和诱发性癌症提供了明确的解决方案，使其成为更理想的癌症治疗选择。例如，Kite 的 Tecartus (brexucabtagene autoleucel) 已获得 FDA 批准用于治疗復发性或难治性前体 B 细胞急性淋巴细胞白血病。

预计全世界恶性肿瘤病例数量的增加将推动对有效治疗和各种策略的需求，以对抗不断增加的恶性肿瘤发病率。此外，市场上的技术进步有望为新疗法提供新的机会。因此，产品批准的数量正在增加。例如，2022 年 3 月，欧洲医学管理局建议有条件上市许可 Carvykti（ciltacabtagene autoleucel）用于治疗復发难治性多发性骨髓瘤受试者。

这个市场受到世界各国政府和国家癌症协会的有利支持的积极推动。人们越来越关注增加癌症基因治疗的研究经费。例如，2021 年 12 月，一个名为 DARE-NL 的荷兰平台（荷兰）从 KWF 荷兰癌症协会获得了 520 万美元的赠款。这笔赠款将使 DARE-NL 能够提升穷人可用的细胞和基因治疗策略。

亚洲製造商专注于可大规模生产的低复杂性分子，因此对新技术和復杂技术的投资相对较低。因此，投资于高收益、低成本的技术是欧洲和北美等其他发达地区製造商规避竞争压力的一种选择。

在该市场运营的新兴市场公司正专注于合作研究，以开发有效的癌症基因治疗药物。例如，2022 年 8 月，Gensaic 与 Ovid Therapeutics 签订合作研究协议，利用该公司专有的噬菌体衍生颗粒基因治疗平台开发最多三种用于中枢神经系统适应症的基因治疗药物。

癌症基因治疗市场报告亮点

由于对在基因水平上了解癌症状况、基因引导免疫疗法和个性化医疗的需求不断增加，市场正面临一个重大转折点。

由于基因引导免疫治疗研究的进展，基因引导免疫治疗领域将在2021年占据最大市场份额

由于对新型基因疗法的需求不断增加以及 FDA 批准癌症基因疗法的数量不断增加，生物製药公司在 2021 年占据了最大份额。由于该领域研发活动的增加，预计生物製药公司在预测期内增长最快

由于主要参与者的存在以及政府和国家癌症研究所对推进该地区癌症研究的支持不断增加，北美将在 2021 年主导该市场

目录

1 癌症基因治疗市场：研究方法和范围

  • 市场细分
    • 段范围
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR内部数据库
    • 次要信息
    • 初步调查
    • 第一次调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：使用自下而上的方法按国家/地区进行市场预测
      • 方法 2：使用自上而下的方法逐个国家/地区进行市场估算
  • 全球市场：复合年增长率计算
  • 区域市场：CAGR 计算
  • 二级信息列表
  • 目的
  • 缩略语表

2 癌症基因治疗市场：执行摘要

  • 癌症基因治疗市场：市场前景
    • 市场概况

3 癌症基因治疗市场：行业展望

  • 市场系列展望
    • 父市场血统展望
    • 相关/子公司市场展望
  • 绘製渗透率和增长前景
  • 市场动态
    • 市场驱动力
      • 医药行业高增长
      • 研发投入增加，抗癌新药需求增加
      • 癌症发病率增加
      • 技术进步
    • 市场约束因素分析
      • 产品价格高
      • 不道德地使用基因疗法
  • SWOT 分析，按因素（政治和法律、经济和技术）
  • 行业分析 - 搬运工
  • 赎回和监管场景
  • 重大交易和战略联盟
    • 新产品发布
    • 获得
    • 扩张
    • 合伙
    • 营销和推广

第四章癌症基因治疗市场：竞争格局

  • 主要市场进入者的最新发展和影响分析
    • Ansoff Matrix
  • 公司分类
    • 创新者
      • 市场差异化因素
  • 供应商情况
    • 主要经销商及渠道合作伙伴名单
    • 主要客户
    • 2021 年主要参与者的市场份额分析
  • 上市公司
    • 竞争仪錶盘分析
  • 民营企业
    • 主要初创企业名单
  • Regional Network Map

5 癌症基因治疗市场：治疗分析

  • 癌症基因治疗市场：治疗波动分析
  • 溶瘤病毒疗法
  • 基因引导的免疫疗法
  • 基因转移

6 癌症基因治疗市场：最终用途分析

  • 癌症基因治疗市场：最终用途变异分析
  • 调查
  • 生物製药公司
  • 诊断中心
  • 其他最终用途

第 7 章癌症基因治疗市场：区域业务分析

  • 2021 年和 2030 年按国家/地区划分的市场份额分析
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 法国
      • 意大利
      • 西班牙
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 韩国
      • 澳大利亚
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

8 癌症基因治疗市场：公司概况

  • 公司简介
    • Abeona Therapeutics Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Asklepios BioPharmaceutical Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Celgene（Bristol-Myers Squibb Company）
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Elevate Bio
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • GlaxoSmithKline Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bluebird bio Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Genelux Corporation
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • OncoGenex Pharmaceuticals Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Introgen Therapeutics Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Altor Bioscience Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Merck &Co., Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • GenVec
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • BioCancell Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
  • 其他主要参与者名单
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 8.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.99% from 2022 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine
  • The gene induced immunotherapy segment held the largest share in 2021 due to increase in the advancement in gene induced immunotherapy research
  • Biopharmaceutical companies held the largest market share in 2021 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field
  • North America dominated the market in 2021 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region

Table of Contents

Chapter 1 Cancer Gene Therapy Market: Methodology And Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
      • 1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Regional Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:
  • 1.11 List of Abbreviations

Chapter 2 Cancer Gene Therapy Market: Executive Summary

  • 2.1 Cancer Gene Therapy Market: Market Outlook
    • 2.1.1 Market Summary

Chapter 3 Cancer Gene Therapy Market: Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
      • 3.3.1.1 High growth of the pharmaceutical industry
      • 3.3.1.2 Rising R&D investements and demand for novel cancer therapeutics
      • 3.3.1.3 Increased incidence of cancers
      • 3.3.1.4 Technological advancements
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 High product prices
      • 3.3.2.2 Unethical use of gene therapy
  • 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Reimbursement & Regulatory Scenario
  • 3.7 Major Deals & Strategic Alliances
    • 3.7.1 New Product Launch
    • 3.7.2 Acquisition
    • 3.7.3 Expansion
    • 3.7.4 Partnerships
    • 3.7.5 Marketing & Promotions

Chapter 4 Cancer Gene Therapy Market: Competitive Landscape

  • 4.1 Recent Developments & Impact Analysis, By Key Market Participants
    • 4.1.1 Ansoff Matrix
  • 4.2 Company Categorization
    • 4.2.1 Innovators
      • 4.2.1.1 Market Differentiators
  • 4.3 Vendor Landscape
    • 4.3.1 List Of Key Distributors And Channel Partners
    • 4.3.2 Key Customers
    • 4.3.3 Key Company Market Share Analysis, 2021
  • 4.4 Public Companies
    • 4.4.1 Competitive Dashboard Analysis
  • 4.5 Private Companies
    • 4.5.1 List Of Key Emerging Companies
  • 4.6 Regional Network Map

Chapter 5 Cancer Gene Therapy Market: Therapy Analysis

  • 5.1 Cancer Gene Therapy Market: Therapy Movement Analysis
  • 5.2 Oncolytic Virotherapy
    • 5.2.1 Oncolytic virotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Gene Induced Immunotherapy
    • 5.3.1 Gene induced immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4 Gene Transfer
    • 5.3.1 Gene transfer market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Gene Therapy Market: End-Use Analysis

  • 6.1 Cancer Gene Therapy Market: End-Use Movement Analysis
  • 6.2 Research Institutes
    • 6.2.1 Research institutes based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Biopharmaceutical Companies
    • 6.3.1 Biopharmaceutical companies based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Diagnostic Centres
    • 6.4.1 Diagnostic centres based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5 Other End-use
    • 6.5.1 Other end-use based cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Gene Therapy Market: Regional Business Analysis

  • 7.1 Market Share Analysis by Country, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Italy
      • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Spain
      • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 South Korea
      • 7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.6 Australia
      • 7.1.3.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.3 Mexico
      • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.4 Argentina
      • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East And Africa
      • 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.2 South Africa
      • 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.3 Saudi Arabia
      • 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.4 UAE
      • 7.1.5.4.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cancer Gene Therapy Market: Company Profiling

  • 8.1 Company Profiles
    • 8.1.1 Abeona Therapeutics Inc.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Product benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 Asklepios BioPharmaceutical Inc.
      • 8.1.2.1 Company overview
      • 8.1.2.2 Financial performance
      • 8.1.2.3 Product benchmarking
      • 8.1.2.4 Strategic initiatives
    • 8.1.3 Celgene(Bristol-Myers Squibb Company)
      • 8.1.3.1 Company overview
      • 8.1.3.2 Financial performance
      • 8.1.3.3 Product benchmarking
      • 8.1.3.4 Strategic initiatives
    • 8.1.4 Elevate Bio
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Product benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 GlaxoSmithKline Inc.
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Product benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 Bluebird bio Inc.
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Product benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 Genelux Corporation
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Product benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 OncoGenex Pharmaceuticals Inc.
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Product benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Introgen Therapeutics Inc.
      • 8.1.9.1 Company overview
      • 8.1.9.2 Financial performance
      • 8.1.9.3 Product benchmarking
      • 8.1.9.4 Strategic initiatives
    • 8.1.10 Altor Bioscience Inc.
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Product benchmarking
      • 8.1.10.4 Strategic initiatives
    • 8.1.11 Merck & Co., Inc.
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Product benchmarking
      • 8.1.11.4 Strategic initiatives
    • 8.1.12 GenVec
      • 8.1.12.1 Company overview
      • 8.1.12.2 Financial performance
      • 8.1.12.3 Product benchmarking
      • 8.1.12.4 Strategic initiatives
    • 8.1.13 BioCancell Inc.
      • 8.1.13.1 Company overview
      • 8.1.13.2 Financial performance
      • 8.1.13.3 Product benchmarking
      • 8.1.13.4 Strategic initiatives
  • 8.2 List of Other Key Players

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Incidence of Diseases
  • TABLE 4 Global Cancer Gene Therapy Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 5 Global Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 6 Global Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 7 North America Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 8 North America Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 9 North America Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 12 Canada Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 14 Europe Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 15 Europe Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 17 Germany Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 18 Germany Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 19 U.K. Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 20 U.K. Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 21 France Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 22 France Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 23 Italy Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 24 Italy Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 25 Spain Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 26 Spain Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 27 Asia Pacific Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 28 Asia Pacific Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 29 Asia pacific Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 30 Japan Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 31 Japan Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 32 China Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 33 China Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 34 India Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 35 India Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 36 South Korea Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 37 South Korea Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 38 Australia Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 39 Australia Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 40 Latin America Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 41 Latin America Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 42 Latin America Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 43 Brazil Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 44 Brazil Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 45 Mexico Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 46 Mexico Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 47 Argentina Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 48 Argentina Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 49 Middle East & Africa Cancer Gene Therapy Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 50 Middle East & Africa Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 51 Middle East & Africa Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 52 Saudi Arabia Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 53 Saudi Arabia Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 54 South Africa Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 55 South Africa Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)
  • TABLE 56 UAE Cancer Gene Therapy Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 57 UAE Cancer Gene Therapy Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Information Procurement
  • FIG. 2 Primary Research Pattern
  • FIG. 3 Market Research Approaches
  • FIG. 4 Value Chain-Based Sizing & Forecasting
  • FIG. 5 Market Formulation & Validation
  • FIG. 6 Cancer Gene Therapy, Market Segmentation
  • FIG. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • FIG. 10 Penetration & Growth Prospect Mapping
  • FIG. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 12 Porter's Five Forces Analysis
  • FIG. 13 Market Penetration Vs Growth Prospect Mapping, 2021
  • FIG. 14 Regional Marketplace: Key Takeaways
  • FIG. 15 Global Cancer Gene Therapy Market, for Therapy, 2018 - 2030 (USD Million)
  • FIG. 16 Global Cancer Gene Therapy Market, for Oncolytic Virotherapy, 2018 - 2030 (USD Million)
  • FIG. 17 Global Cancer Gene Therapy Market, for Gene Induced Immunotherapy, 2018 - 2030 (USD Million)
  • FIG. 18 Global Cancer Gene Therapy Market, for Gene Transfer, 2018 - 2030 (USD Million)
  • FIG. 19 Global Cancer Gene Therapy Market, for End-Use, 2018 - 2030 (USD Million)
  • FIG. 20 Global Cancer Gene Therapy Market, for Research Institutes, 2018 - 2030 (USD Million)
  • FIG. 21 Global Cancer Gene Therapy Market, for BiopharmaceuticalCompanies, 2018 - 2030 (USD Million)
  • FIG. 22 Global Cancer Gene Therapy Market, for Diagnostic Centers, 2018 - 2030 (USD Million)
  • FIG. 23 Regional Outlook, 2021 & 2030
  • FIG. 24 North America Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 25 U.S. Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 26 Canada Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 27 Europe Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 28 Germany Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 29 U.K. Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 30 France Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 31 Italy Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 32 Spain Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 33 Asia Pacific Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 34 Japan Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 35 China Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 36 India Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 37 Australia Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 38 South Korea Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 39 Latin America Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 40 Brazil Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 41 Mexico Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 42 Argentina Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 43 Middle East and Africa Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 44 South Africa Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 45 Saudi Arabia Cancer Gene Therapy Market, 2018 - 2030 (USD Million)
  • FIG. 46 UAE Cancer Gene Therapy Market, 2018 - 2030 (USD Million)